Powered by


                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS







   Forum Archives





















   Primary Care






   Other Sections


   Research Tools

   Medical Tutorials

   Medical Software




Back to Psychiatry Articles

Monday 26th March, 2006

Use of serotonin reuptake inhibitors (SSRI) might inhibit the growth of colorectal tumors according to The Lancet Oncology.

tellfrnd.gif (30x26 -- 1330 bytes)send to a friend
prntfrnd.gif (30x26 -- 1309 bytes)printer friendly version

  Antidepressants may be linked to suicidal behavior (FDA warning)  

Use of some antidepressants might reduce the risk of developing colorectal cancer, according to researchers reporting in the April issue of The Lancet Oncology. The antidepressants known as selective serotonin reuptake inhibitors (SSRI) "might inhibit the growth of colorectal tumours", says lead investigator Prof Jean-Paul Collet (Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada).

Results from studies of antidepressant use and cancer risk have been inconsistent and focused mainly on cancers of the breast and ovaries. The risk associated with colorectal cancers is unknown. In the USA, about 100 million prescriptions of antidepressants are written every year and SSRI are the most commonly used. Animal studies have suggested that SSRI reduce the growth of colorectal tumours. Therefore, researchers postulated that these drugs might reduce the risk of colorectal cancer in humans.

In the study, researchers identified 3367 cases with colorectal cancer and matched them for age, sex, and calendar time with controls without cancer. After adjustment for non-steroidal antiflammatory use during the same period and SSRI use 6-10 years before diagnosis, they found a decreased risk of cancer for those taking a high (>6.0x10-6 mol per day) SSRI dose 0-5 years before diagnosis.

Prof Collet states: "Further investigation is needed, with more complete assessment of confounders such as lifestyle factors, use of drugs, and comorbidity that might affect the occurence of colorectal cancer".

In an accompanying Reflection and Reaction, Prof Henrik Toft S?ensen (Aarhus University Hospital, Aarhus, Denmark) comments that data from the study "provide interesting insights, but until trial data is available, clinicians should not consider SSRI use solely for chemopreventive purposes".


Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada.

advertisement.gif (61x7 -- 0 bytes)

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 advertisement.gif (61x7 -- 0 bytes)



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.